Boston Scientific Corp. on Tuesday hiked its offer to buy Guidant Corp. to about $27 billion, escalating a bidding war with Johnson & Johnson for the maker of cardiac devices and raising concerns among analysts that the price may be too high.
*For more on this story,
read the full Reuters article.
